Summary of uniQure FY Conference Call - March 02, 2026 Company Overview - **Company**: uniQure (NasdaqGS:QURE) - **Focus**: Gene therapies for neurodegenerative diseases, particularly Huntington's disease and epilepsy Key Points on Huntington's Disease Program (AMT-130) - **Phase 3 Data**: The pivotal phase 1/2 trial showed a 75% slowing of disease progression at three years, measured by the composite Unified Huntington's Disease Rating Scale (UHDRS) [9] - **Total Functional Capacity**: A 60% decline in disease progression was observed, which is significant for FDA approval [9] - **Neurofilament Light**: A decrease from baseline was noted, contrasting with the expected 10%-15% annual increase in neurodegeneration markers [9] - **FDA Interactions**: The FDA granted RMAT designation in early 2024 based on initial data, but later expressed concerns about the Phase 1/2 study being hypothesis-generating and not suitable for BLA submission [15][20] - **Next Steps**: A Type B meeting with the FDA is planned to discuss phase 3 study design and the use of external controls [44][46] - **Patient Community Support**: Strong advocacy from patient groups has been noted, with significant engagement in policy discussions and petitions to the FDA [82][84] Key Points on AMT-260 (Temporal Lobe Epilepsy Program) - **Initial Data**: A case study showed a 92% reduction in seizure frequency in the first patient treated, with no significant adverse events reported [84] - **Current Status**: Six patients have been dosed in the first cohort, with data expected in the second quarter of 2026 [85] - **Future Goals**: Aiming for a 50% or higher reduction in seizures to support progression to pivotal trials [96] Key Points on AMT-191 (Fabry Disease Program) - **Study Progress**: A Phase I/II study is ongoing with 11 patients treated, all of whom are off enzyme replacement therapy [99] - **Outcomes**: Dose-dependent increases in the deficient enzyme have been observed, with ongoing monitoring for long-term outcomes [99] Financial and Strategic Considerations - **Funding Position**: The company has a strong balance sheet with a runway into the second half of 2029, allowing for continued investment in promising programs [104] - **Partnership Strategy**: The company remains open to partnerships but emphasizes the need for data to support investment decisions [105] Safety Profile - **AMT-130 Administration**: The procedure is reported to be safe and well-tolerated, with most adverse events being procedure-related rather than drug-related [64] Regulatory Landscape - **International Engagement**: The company is engaging with regulators outside the U.S. for potential expedited reviews and expanded access pathways [71][74] Conclusion - **Commitment to Patients**: The company is focused on advancing its therapies while ensuring ethical considerations in study designs, particularly for slow-progressing diseases like Huntington's [46][54]

Core Insights - The article identifies 7 hidden multibagger stocks that have shown significant returns and potential upside, emphasizing the importance of selecting stocks with strong fundamentals and growth prospects [1][5]. Group 1: Stock Selection Criteria - Stocks were selected based on a minimum return of 75% over the past year and a market capitalization of at least $1 billion [1]. - The shortlisted stocks were required to have at least 30% potential upside, leading to a ranking of the top 7 stocks [1]. Group 2: Market Outlook - The S&P 500 index is expected to show positive performance for the third consecutive year, with AI adoption potentially driving a productivity boom similar to the late 90s [3]. - Goldman Sachs anticipates that reducing tariff uncertainties could enhance economic security, leading to increased capital deployment in defense, energy, and infrastructure sectors [4]. Group 3: Individual Stock Highlights - **Praxis Precision Medicines, Inc. (NASDAQ:PRAX)**: Achieved a 264% price return over the past year with a potential upside of 33%. The company reported positive results from a key study on a treatment for severe epilepsy [6][8]. - **Solaris Resources Inc. (NYSEAMERICAN:SLSR)**: Recorded a 139% price return with a potential upside of 43.36%. The company is focused on copper and other minerals, with a significant project expected to produce 4.5 million tonnes of Copper Equivalent [10][11]. - **Ouster Inc. (NASDAQ:OUST)**: Experienced a 138.5% price return and has a potential upside of 55.37%. The company is noted for its strong client base and growth prospects in lidar sensor technology [14][15]. - **Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)**: Achieved a 75% price return with a potential upside of 61.3%. The company is advancing a new formulation for hypothyroidism treatment [18][19]. - **Applied Digital Corporation (NASDAQ:APLD)**: Saw a 192.6% price return and has a potential upside of 62.36%. The company is investing in advanced cooling systems for data centers, positioning itself for growth in the AI sector [21][22]. - **IREN Limited (NASDAQ:IREN)**: Recorded a 190.5% price return with a potential upside of 91.23%. Despite recent funding challenges, the company has strong fundamentals supported by a significant AI contract with Microsoft [24][26]. - **UniQURE (NASDAQ:QURE)**: Achieved a 186% price return with a potential upside of 117.16%. The company is developing a gene therapy for Huntington's disease, although it faces regulatory challenges [28][29].

Company Overview - uniQure N.V. (NASDAQ:QURE) specializes in developing gene therapies for rare and severe diseases, including an approved treatment for hemophilia B called HEMGENIX and clinical candidates for Huntington's disease, epilepsy, ALS, and Fabry disease [2] Clinical Data - On September 24, uniQure announced positive Phase I/II results for its gene therapy candidate AMT-130 targeting Huntington's disease, demonstrating a 75% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale and a 60% improvement on Total Functional Capacity after 36 months compared to a matched control group [2] Market Sentiment - Jim Cramer highlighted the positive clinical data but expressed caution due to an insider selling approximately $9 million worth of stock, indicating potential concerns about the stock's future performance after a significant price increase [1]

Core Insights - uniQure N.V. is recognized as one of the best performing healthcare stocks, focusing on gene therapy for severe medical conditions [1] - The company has achieved significant clinical milestones, particularly with AMT-130 for Huntington's disease, showing a 75% slowing of disease progression over three years [2] - Financially, uniQure has raised $300 million through a public offering and secured a $175 million senior secured term loan to support its development and commercialization efforts [3] - Analysts have responded positively to uniQure's breakthroughs and funding, leading to strong buy ratings and optimistic price targets [4] Company Overview - uniQure N.V. specializes in gene therapy, with a pipeline that includes treatments for hemophilia B and Huntington's disease [1] - The company is advancing multiple gene therapy candidates targeting rare diseases, including AMT-260 for mesial temporal lobe epilepsy, AMT-162 for ALS, and AMT-191 for Fabry disease [3] Clinical Developments - Positive topline results from pivotal Phase I/II trials of AMT-130 have set the stage for a Biologics License Application (BLA) submission to the FDA in early 2026 [2] - The combination of groundbreaking data from AMT-130 and a diversified pipeline positions uniQure for potential transformative impacts on patients [4]